ALDX
HealthcareAldeyra Therapeutics, Inc.
$4.24
$-0.43 (-9.21%)
Jan 5, 2026
Price History (1Y)
Analysis
Aldeyra Therapeutics, Inc. is a biotechnology company in the healthcare sector with a market capitalization of $255.09 million. The company operates at a relatively small scale with 8 employees. Financially, Aldeyra has reported net income of -$43,193,920 and EBITDA of -$44,923,856 over the trailing twelve months, resulting in gross margin, operating margin, and profit margin all being 0.0%. The company's returns on equity and assets are -64.3% and -28.9%, respectively. Aldeyra has a debt-to-equity ratio of 31.56 and cash reserves of $75.30 million. Aldeyra's valuation metrics include a forward price-to-earnings ratio of 12.95, with a negative EV/EBITDA of -4.92. The company does not pay dividends, resulting in a payout ratio of 0.0%.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Aldeyra Therapeutics, Inc.
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated and metabolic diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platform, including ADX 248, ADX 743, ADX 631, ADX 246, and other product candidates in development for inflammatory and metabolic diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
Visit website →Key Statistics
- Market Cap
- $255.09M
- P/E Ratio
- N/A
- 52-Week High
- $7.20
- 52-Week Low
- $1.14
- Avg Volume
- 994.47K
- Beta
- 0.85
Company Info
- Industry
- Biotechnology
- Exchange
- NCM
- Country
- United States
- Employees
- 8